SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs > Viking Therapeutics, Inc. (VKTX)

The trial was slated to enroll more than

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
ZeWaffleBaron Member Profile
 
Followed By 7
Posts 174
Boards Moderated 0
Alias Born 04/26/17
160x600 placeholder
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/11/2017 4:26:56 PM
Viking Therapeutics Announces Closing of Public Offering of Common Stock "PR Newswire (US)" - 12/11/2017 4:15:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 12/7/2017 4:40:46 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/7/2017 6:04:54 AM
Viking Therapeutics Announces Pricing of $12.8 Million Public Offering of Common Stock "PR Newswire (US)" - 12/6/2017 8:08:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 12/5/2017 4:30:49 PM
Viking Therapeutics Announces Proposed Public Offering of Common Stock "PR Newswire (US)" - 12/5/2017 4:18:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/28/2017 7:08:18 AM
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture "PR Newswire (US)" - 11/28/2017 7:02:00 AM
Investor Expectations to Drive Momentum within Vector Group, NovoCure, ORBCOMM, Ecolab, Bank of America, and Viking Therapeut... "GlobeNewswire Inc." - 11/20/2017 8:20:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/8/2017 5:12:26 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/8/2017 4:13:01 PM
Viking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update "PR Newswire (US)" - 11/8/2017 4:05:00 PM
Viking Therapeutics to Report Financial Results for Third Quarter 2017 on November 8, 2017 "PR Newswire (US)" - 11/1/2017 7:30:00 AM
Notice of Effectiveness (effect) "Edgar (US Regulatory)" - 10/27/2017 6:02:23 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) "Edgar (US Regulatory)" - 10/26/2017 4:54:21 PM
Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at... "PR Newswire (US)" - 10/24/2017 7:05:00 AM
Viking Therapeutics Presents Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy ... "PR Newswire (US)" - 10/23/2017 7:05:00 AM
Securities Registration Statement (s-1) "Edgar (US Regulatory)" - 10/17/2017 4:49:11 PM
Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleuko... "PR Newswire (US)" - 10/4/2017 7:05:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 9/29/2017 4:46:11 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/29/2017 7:06:35 AM
Viking Therapeutics Announces Purchase Agreements for up to $16.25 Million with Lincoln Park Capital "PR Newswire (US)" - 9/29/2017 7:05:00 AM
Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settin... "PR Newswire (US)" - 9/25/2017 7:30:00 AM
Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatit... "PR Newswire (US)" - 9/11/2017 7:05:00 AM
ZeWaffleBaron   Wednesday, 10/04/17 06:43:29 AM
Re: zoomlik post# 697
Post # of 1146 
The trial was slated to enroll more than that, and they chose to complete enrollment with the current number. This was a decent length trial, they should have had plenty of time for interim analyses of data. You feel that they mistakenly stopped early and will not have statistically significance, and that will be the error?! Lol! I've worried about many things in this space, but that ain't one of them. Do some DD before you throw your money somewhere. I doubt you are worrying here for free tho

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist